Mn Services Vermogensbeheer B.V. Decreases Stake in Illumina, Inc. (NASDAQ:ILMN)

Mn Services Vermogensbeheer B.V. reduced its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 7.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 57,400 shares of the life sciences company's stock after selling 4,500 shares during the quarter. Mn Services Vermogensbeheer B.V.'s holdings in Illumina were worth $4,554,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Fourth Dimension Wealth LLC bought a new position in shares of Illumina during the fourth quarter valued at approximately $40,000. Bank Julius Baer & Co. Ltd Zurich purchased a new position in Illumina during the 4th quarter valued at $45,000. Assetmark Inc. grew its position in Illumina by 954.8% in the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock valued at $44,000 after acquiring an additional 296 shares during the last quarter. Lee Danner & Bass Inc. bought a new position in Illumina in the 4th quarter valued at $48,000. Finally, V Square Quantitative Management LLC increased its stake in Illumina by 50.6% in the fourth quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company's stock worth $52,000 after purchasing an additional 132 shares during the period. Institutional investors own 89.42% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ILMN. Royal Bank Of Canada decreased their target price on Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a research report on Tuesday, April 8th. Piper Sandler decreased their price objective on Illumina from $190.00 to $185.00 and set an "overweight" rating for the company in a report on Thursday, May 15th. Robert W. Baird lowered their price objective on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a research note on Wednesday, March 5th. Morgan Stanley dropped their target price on shares of Illumina from $136.00 to $100.00 and set an "equal weight" rating on the stock in a report on Monday, May 12th. Finally, Canaccord Genuity Group raised their target price on shares of Illumina from $87.00 to $99.00 and gave the company a "hold" rating in a research report on Wednesday, June 11th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $126.94.

Illumina Stock Up 0.9%

Shares of NASDAQ ILMN traded up $0.79 during trading hours on Thursday, hitting $90.26. 2,019,090 shares of the stock were exchanged, compared to its average volume of 2,277,489. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66. The firm has a fifty day moving average price of $80.03 and a 200-day moving average price of $101.80. The company has a quick ratio of 1.48, a current ratio of 1.86 and a debt-to-equity ratio of 0.63. The company has a market cap of $14.29 billion, a PE ratio of -14.87, a PEG ratio of 1.76 and a beta of 1.32.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.01. Illumina had a negative net margin of 22.25% and a positive return on equity of 25.54%. The business had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.03 billion. During the same period in the previous year, the company earned $0.98 earnings per share. The business's revenue for the quarter was down 1.4% on a year-over-year basis. On average, sell-side analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Insider Activity at Illumina

In other Illumina news, CFO Ankur Dhingra purchased 6,100 shares of the stock in a transaction on Monday, May 12th. The stock was acquired at an average price of $81.21 per share, with a total value of $495,381.00. Following the completion of the acquisition, the chief financial officer now owns 24,906 shares in the company, valued at $2,022,616.26. The trade was a 32.44% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 2.60% of the stock is currently owned by corporate insiders.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.